Title: Methods and Compositions for Treating and Preventing Neurologic Disorders
Patent Number: 7,786,090
Filed: March 1, 2007
Lead Inventor: Azad Bonni, Harvard University
The intention, the patent's abstract states, "provides methods for treating or reducing neurologic disorders."
It specifically claims the use of interfering RNA to down-regulate human prolyl isomerase Pin 1.
Title: Composition and Method of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases
Patent Number: 7,786,092
Filed: April 9, 2009
Lead Inventor: Yijia Liu, Intradigm (Silence Therapeutics)
The patent, its abstract states, claims "compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control [neovascularization] through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological [neovascularization] tissues.
"Tissue-targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference are provided," the abstract adds. "The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of [neovascularization] diseases such as cancer, ocular disease, arthritis, and inflammatory diseases."
Title: Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism
Patent Number: 7,786,290
Filed: June 14, 2004 PCT Filed: June 14, 2004
Lead Inventor: Claudia Woppman, Alnylam Pharmaceuticals
The invention relates to "a method for the targeted selection of a double-stranded ribonucleic acid consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least [one] end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length [and] … the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base," the patent's abstract states. Further, "the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs."
Title: Compositions and Methods for Short Interfering Nucleic Acid Inhibition of Na v1.8
Patent Number: 7,786,291
Filed: Oct. 26, 2005
Lead Inventor: Sameer Goregaoker, Schering
"The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain," according to the patent's abstract.
Title: Recombinant DNA Constructs [Containing] Engineered Plant microRNAs and Methods for Controlling Gene Expression
Patent Number: 7,786,350
Filed: Oct. 10, 2006
Lead Inventor: Edwards Allen, Monsanto Technology
The invention "provides constructs containing engineered miRNAs or miRNA precursors derived from a maize miR408b, transgenic plant cells, plants, and seeds containing such constructs, and methods for their use," the patent's abstract states.
Title: Amphoteric Liposomes
Patent Number: 7,780,983
Filed: Oct. 31, 2006
Lead Inventor: Steffen Panzer, Novosom (Marina Biotech)
The patent, its abstract states, claims "amphoteric liposomes … [comprising] positive and negative membrane-based or membrane-forming charge carriers, as well as the use of these liposomes."
Title: RNA Antagonist Compounds for the Modulation of PCSK9
Application Number: 20100216864
Filed: Oct. 9, 2007 PCT Filed: Oct. 9, 2007
Lead Inventor: Ellen Marie Straarup, Technical University of Denmark
The invention comprises "compounds, compositions, and methods for modulating the expression of PCSK9," the patent application's abstract states. "In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridizable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed."
Title: microRNA Compositions in the Treatment of VEGF-Mediated Disorders
Application Number: 20100216865
Filed: Sept. 29, 2008 PCT Filed: Sept. 29, 2008
Inventor: Jack Elias
"The invention provides methods of treating diseases caused by the over-production of a VEGF polypeptide by administering miRNA or miRNA inhibitor compositions to decrease at least one activity of a VEGF polypeptide," the patent application's abstract states.
Title: RNAi Modulation of ApoB and Uses Thereof
Application Number: 20100216866
Filed: March 19, 2010
Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals
"The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the down-regulation of apolipoprotein B by chemically modified oligonucleotides," according to the patent application's abstract.
Title: Agents, Compositions, and Methods for Treating Pathologies in which Regulating an AChE-Associated Biological Pathway is Beneficial
Application Number: 20100216868
Filed: March 6, 2008 PCT Filed: March 6, 2008
Lead Inventor: Hermona Soreq, Hebrew University of Jerusalem
The invention, the patent application's abstract states, "provides agents which are capable of regulating the function of a microRNA component which can be used to regulate an AChE-associated biological pathway. In addition, the … invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis, aberrant cholinergic signaling, abnormal hematopoietic proliferation and/or differentiation, cellular stress, exposure to inflammatory response-inducing agents, and/or exposure to organophosphates or other AChE inhibitors."
Titles: RNAi Inhibition of Alpha-ENaC Expression
Application Numbers: 20100216971, 20100216972
Filed: April 30, 2010
Lead Inventor: Gino Van Heeke, Novartis
The inventions, the patent applications' abstracts state, relate to "compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides."